Simplifying Survivorship Care Planning

^aMissing for 1 colorectal "2-visit" participant.

^aThe first number is the number of participants whose SCPs recommended visits or tests or procedures, including recommendations of "as needed" or "at least" a minimum; the second number reflects the frequency of SCP recommendations against a test/procedure. "—" = not applicable; CBC = complete blood count; CEA = carcinoembryonic antigen; CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography; PSA = prostate-specific antigen.
^bCalculation of the mean (range) maximum excludes participants with recommendations against or a recommendation of "as needed" or "at least."
^cCancer care team includes visits to providers in any of the following specialties: radiation oncology, medical oncology, or surgery.
^dOther includes gynecology, plastic surgery, physical therapy, and genetic counseling.
^eTotal was calculated by taking the sum of the minimum number of recommendations and sum of the maximum number of recommendations across visits, tests or procedures, and nonoral medications for each patient and then calculating the corresponding summary statistics (mean, range) among the patient-level sums.
^fFor some participants, a combination of the 2 medications was recommended.

^aFisher's exact test. All statistical tests were 2-sided. "—" = not applicable.
^bOveruse of primary care was not considered an option.
^cCancer care team includes visits to providers in any of the following specialties: radiation oncology, medical oncology, or surgery.
^dOther includes gynecology, plastic surgery, physical therapy, genetics counseling.

^aFisher's exact test. All statistical tests were 2-sided. "—" = not applicable.
^bOveruse of primary care was not considered an option.
^cCancer care team includes visits to providers in any of the following specialties: radiation oncology, medical oncology, or surgery.
^dOther includes gynecology, plastic surgery, physical therapy, genetics counseling.

Authors and Disclosures

Claire Snyder, PhD^1–3*, Youngjee Choi, MD¹, Amanda L. Blackford, ScM³, Jennifer DeSanto, RN, MS², Nancy Mayonado, MS⁴, Susan Rall, MEd⁴, Sharon White, BA², Janice Bowie, PhD, MPH², David E. Cowall, MD⁴, Fabian Johnston, MD, MHS^1,3, Robert L. Joyner Jr, PhD, RRT⁴, Joan Mischtschuk, RN, MS⁴, Kimberly S. Peairs, MD^1,3, Elissa Thorner, MHS³, Phuoc T. Tran, MD, PhD^1,3, Antonio C. Wolff, MD^1,3 and Katherine C. Smith, PhD^2,3 and the SSCP Stakeholder Advisory Board

¹Johns Hopkins University School of Medicine, Baltimore, MD, USA; ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ³Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA and ⁴TidalHealth Richard A. Henson Research Institute, Salisbury, MD, USA

*Correspondence to
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, 624 N. Broadway, 6th Floor, Baltimore, MD 21205, USA (e-mail: csnyder@jhu.edu).

Disclosures
Dr Snyder receives research funding from Genentech and Pfizer through Johns Hopkins and previously received royalties from UptoDate for authorship related to survivorship. Dr Tran received research funding from Astellas Pharm, Bayer Healthcare, and RefleXion Medial Inc; personal fees from Consulting from RefleXion, grants from RefleXion, personal fees from Noxopharm, Janssen-Taris Biomedical, Myovant and AstraZeneca outside the submitted work; and has a patent 9114158—Compounds and Methods of Use in Ablative Radiotherapy licensed to Natsar Pharm. Dr Johnston is funded through the AHRQ 1K08HS024736. Dr Peairs and Dr Choi receive research funding from a Merck Foundation grant through Johns Hopkins. All other authors have no conflicts of interest to declare.

Author contributions
Conceptualization (CFS, ET, ACW, KCS), Data Curation (ALB, JD, NM, SR, SW), Formal analysis (ALB), Funding acquisition (CFS, ALB, JB, JM, KSP, EDT, PTT, ACW, KCS), Investigation (all authors), Methodology (CFS, YC, ALB, JD, NM, SR, SW, KCS), Project administration (CFS, DEC, RLJ, JM, KCS), Resources (FJ, PTT, ACW), Supervision (CFS, DEC, RLJ, JM, KCS), Validation (CFS, ALB, JD, NM, SR, SW, KCS), Visualization (CFS), Writing—original draft (CFS), Writing—review and editing (all authors).